Nektar Therapeutics Aktie
WKN: 165417 / ISIN: US6402681083
27.10.2021 00:00:00
|
Nektar to Announce Financial Results for the Third Quarter 2021 on Thursday, November 4, 2021, After Close of U.S.-Based Financial Markets
SAN FRANCISCO, Oct. 26, 2021 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter 2021 on Thursday, November 4, 2021, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time.
The press release and live audio-only webcast of the conference call can be accessed through a link that is posted on the Home Page and Investors section of the Nektar website: https://ir.nektar.com/. The web broadcast of the conference call will be available for replay through December 6, 2021.
To access the conference call, follow these instructions:
Dial: (877) 881-2183 (U.S); (970) 315-0453 (international)
Conference ID: 8264398 (Nektar Therapeutics is the host)
About Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical company with a robust, wholly owned R&D pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug development programs and capabilities may be found online at https://www.nektar.com.
Contacts:
For Investors:
Vivian Wu of Nektar Therapeutics
628-895-0661
View original content to download multimedia:https://www.prnewswire.com/news-releases/nektar-to-announce-financial-results-for-the-third-quarter-2021-on-thursday-november-4-2021-after-close-of-us-based-financial-markets-301409217.html
SOURCE Nektar Therapeutics

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Nektar Therapeuticsmehr Nachrichten
18.04.25 |
NASDAQ Composite Index-Titel Nektar Therapeutics-Aktie: So viel Verlust wäre bei einem Investment in Nektar Therapeutics von vor 10 Jahren angefallen (finanzen.at) | |
17.04.25 |
NASDAQ-Handel: NASDAQ Composite beginnt Donnerstagshandel in der Gewinnzone (finanzen.at) | |
16.04.25 |
Börse New York: NASDAQ Composite präsentiert sich leichter (finanzen.at) | |
15.04.25 |
Zurückhaltung in New York: NASDAQ Composite verliert letztendlich (finanzen.at) | |
15.04.25 |
Freundlicher Handel in New York: So performt der NASDAQ Composite am Mittag (finanzen.at) | |
11.04.25 |
Optimismus in New York: NASDAQ Composite beendet die Freitagssitzung im Plus (finanzen.at) | |
11.04.25 |
Zuversicht in New York: NASDAQ Composite in Grün (finanzen.at) | |
11.04.25 |
Aufschläge in New York: NASDAQ Composite liegt mittags im Plus (finanzen.at) |
Analysen zu Nektar Therapeuticsmehr Analysen
Aktien in diesem Artikel
Nektar Therapeutics | 0,56 | -15,55% |
|